These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3128804)

  • 21. Comparison of the behavioral effects of para-chloroamphetamine, chlordimeform, quipazine, and intraventricular serotonin in the rat.
    Pfister WR; Noland V; Lowy MT; Nichols DE; Yim GK
    Commun Psychopharmacol; 1978; 2(4):287-95. PubMed ID: 729354
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of quipazine and methysergide on play in juvenile rats.
    Normansell L; Panksepp J
    Pharmacol Biochem Behav; 1985 May; 22(5):885-7. PubMed ID: 2989950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A receptor.
    Smith RL; Barrett RJ; Sanders-Bush E
    J Pharmacol Exp Ther; 1995 Nov; 275(2):1050-7. PubMed ID: 7473132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of quipazine, a serotonin receptor agonist, on serum corticosterone concentration in rats.
    Fuller RW; Snoddy HD; Clemens JA
    Endocr Res Commun; 1978; 5(2):161-71. PubMed ID: 309816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stimulus generalization by fenfluramine in a quipazine-ketanserin drug discrimination is not dependent on indirect serotonin release.
    Smith RL; Gresch PJ; Barrett RJ; Sanders-Bush E
    Pharmacol Biochem Behav; 2002 May; 72(1-2):77-85. PubMed ID: 11900772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of serotonin receptor antagonists on punished responding maintained by stimulus-shock termination or food presentation in squirrel monkeys.
    Brady LS; Barrett JE
    J Pharmacol Exp Ther; 1985 Jul; 234(1):106-12. PubMed ID: 4009495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonergic stimulation of prolactin release in the young turkey (Meleagris gallopavo).
    Fehrer SC; Silsby JL; El Halawani ME
    Gen Comp Endocrinol; 1983 Dec; 52(3):400-8. PubMed ID: 6230284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The quipazine- and TFMPP-increased conditioned avoidance response in rats: role of 5HT1C/5-HT2 receptors.
    Alhaider AA; Ageel AM; Ginawi OT
    Neuropharmacology; 1993 Dec; 32(12):1427-32. PubMed ID: 8152532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentiation between the stimulus effects of l-5-hydroxytryptophan and LSD.
    Cunningham KA; Callahan PM; Appel JB
    Eur J Pharmacol; 1985 Jan; 108(2):179-86. PubMed ID: 3156756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of a difference between ketanserin and ritanserin in central vs. peripheral serotonin receptor antagonism.
    Cohen ML; Bloomquist WL; Snoddy HD; Fuller RW
    Life Sci; 1989; 45(13):1185-9. PubMed ID: 2507847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different serotonin receptor types participate in 5-hydroxytryptophan-induced gonadotropins and prolactin release in the female infantile rat.
    Lacau-Mengido IM; Libertun C; Becú-Villalobos D
    Neuroendocrinology; 1996 May; 63(5):415-21. PubMed ID: 8738578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of imipramine and serotonin-2 agonists and antagonists on serotonin-2 and beta-adrenergic receptors following noradrenergic or serotonergic denervation.
    Eison AS; Eison MS; Yocca FD; Gianutsos G
    Life Sci; 1989; 44(19):1419-27. PubMed ID: 2785627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MDL 72222, ketanserin, and methysergide pretreatments fail to alter breaking points on a progressive ratio schedule reinforced by intravenous cocaine.
    Lacosta S; Roberts DC
    Pharmacol Biochem Behav; 1993 Jan; 44(1):161-5. PubMed ID: 8430119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Behavioral effects of dopaminergic agonists and antagonists alone and in combination in the squirrel monkey.
    Katz JL; Witkin JM
    Psychopharmacology (Berl); 1993; 113(1):19-25. PubMed ID: 7862823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variability in the effects of 4-bromo-2,5-dimethoxyamphetamine (DOB) on operant behavior of squirrel monkeys.
    McKearney JW
    Pharmacol Biochem Behav; 1988 Feb; 29(2):281-5. PubMed ID: 3362922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of head twitch response to quipazine in rats by chronic amitriptyline but not fluvoxamine or citalopram.
    Pawłowski L; Melzacka M
    Psychopharmacology (Berl); 1986; 88(3):279-84. PubMed ID: 3083448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective effects of the D1 dopamine receptor agonist, SKF 38393, on behavior maintained by cocaine injection in squirrel monkeys.
    Katz JL; Witkin JM
    Psychopharmacology (Berl); 1992; 109(1-2):241-4. PubMed ID: 1365665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Behavioral effects of quipazine in the cat.
    Trulson ME; Brandstetter JW; Crisp T; Jacobs BL
    Eur J Pharmacol; 1982 Mar; 78(3):295-305. PubMed ID: 6461558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of 5-HT2 receptors in the wet-dog shake behaviour induced by 5-hydroxytryptophan in the rat.
    Yap CY; Taylor DA
    Neuropharmacology; 1983 Jul; 22(7):801-4. PubMed ID: 6604883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists.
    Glennon RA; Young R; Rosecrans JA
    Eur J Pharmacol; 1983 Jul; 91(2-3):189-96. PubMed ID: 6617740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.